Currently out of the existing stock ratings of Christopher Neyor, 7 are a BUY (87.5%), 1 are a SELL (12.5%).

Christopher Neyor

Work Performance Price Targets & Ratings Chart

Analyst Christopher Neyor works at JPMORGAN with a stock forecast success ratio of 11.11% fulfilled within 79.67 days on average.

Christopher Neyor’s has documented 15 price targets and ratings displayed on 3 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on PCRX, Pacira Pharmaceuticals at 07-Mar-2024.

Wall Street Analyst Christopher Neyor

Analyst best performing recommendations are on PCRX (PACIRA PHARMACEUTICALS).
The best stock recommendation documented was for PCRX (PACIRA PHARMACEUTICALS) at 7/26/2021. The price target of $75 was fulfilled within 239 days with a profit of $16.09 (27.31%) receiving and performance score of 1.14.

Average potential price target upside

PCRX Pacira Pharmaceuticals KALA Kala Pharmaceuticals ITOS Iteos Therapeutics 

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

43

$13.31 (44.83%)

45

18 days ago

2/13 (15.38%)

$13.35 (45.03%)

878

Buy

38

$8.31 (27.99%)

57

18 days ago

2/9 (22.22%)

$8.35 (28.16%)

432

Buy

57

$27.31 (91.98%)

57

18 days ago

13/24 (54.17%)

$27.35 (92.24%)

233

Buy

45

$15.31 (51.57%)

83

2 months 19 days ago

1/3 (33.33%)

$14.36 (46.87%)

239

Buy

45

$15.31 (51.57%)

58

2 months 25 days ago

0/5 (0%)

$16.14 (55.93%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Christopher Neyor is most bullish on?

Potential upside of $15.31 has been obtained for PCRX (PACIRA PHARMACEUTICALS)

What Year was the first public recommendation made by Christopher Neyor?

On 2017

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?